Skip to Main Content

Riding the coattails of CAR-T cancer therapies, scientists have begun to explore a spin-off: using similar immune cells to treat autoimmune diseases such as type 1 diabetes and prevent rejection of transplanted organs.

In CAR-T therapies, T cells are extracted from a patient’s blood, reprogrammed to attack cancer cells, and then re-infused into the bloodstream to carry out their new assignment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED